SynCardia Systems, a Picard Medical, Inc. company, and the global leader in total artificial heart technology, is pleased to announce that the China National Intellectual Property Administration (“CNIPA”) has notified the Company of the administration’s decision to grant SynCardia its first patent covering the Company’s next-generation total artificial heart. This patent describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle.
This milestone represents a significant step toward realizing SynCardia’s vision of a fully implantable total artificial heart (“Emperor”), providing a life-saving solution to patients suffering from advanced heart failure worldwide. The next-generation Emperor artificial heart design builds upon SynCardia’s proven total artificial heart technology, with innovations aimed at improving patient outcomes and expanding accessibility to life-saving cardiac support.
“We are thrilled to receive this notification from CNIPA, as it reaffirms the global impact of our mission to advance our artificial heart technology,” said Patrick NJ Schnegelsberg, CEO of SynCardia Systems. “This patent is a crucial component of our strategy to bring the SynCardia Total Artificial Heart and the next generation Emperor artificial heart to patients in China.”
SynCardia remains committed to pioneering advancements in its artificial heart technology and expanding its reach to new markets. The Company continues to work closely with international regulatory bodies and partners to ensure the future availability of its current and next-generation total artificial heart to patients worldwide.
